Johnson and Johnson announced that the European Commission had approved the Ebola vaccine to prevent the Ebola virus disease.
Janssen has submitted two Market Authorisation Applications (MAAs), composing two-dosage regimen, Zabdeno (Ad26.ZEBOV), and Mvabea (MVA-BN-Filo).
The vaccine is indicated in the patients to prevent infectious caused because of Zaire ebolavirus species.
The vaccine is designed to induced immunity against the Ebola virus, indicated in both adults and pediatrics. During the clinical evaluation and vaccination initiatives, 60,000 individuals were vaccinated and showed long term safety and immune response against the Ebola virus.
"The approval of our Ebola vaccine symbolizes the progress Janssen has made towards achieving our vision of delivering potentially transformational vaccines to communities most at risk of deadly infectious diseases," said Mathai Mammen, Global Head, Janssen Research & Development.
About Ebola virus:
Recently, there were two Ebola outbreaks reported, both in the African region. Between 2014-16, the epidemic affected the Western African region resulting in 11,000 deaths. In 2018, the epidemic affected the Democratic Republic of the Congo (DRC), resulting in 2,000 deaths; the mortality rate was observed in 65% of the individuals infected with the virus.